Emyria (ASX: EMD) has introduced the Empax global partnership program to enable international drug sponsors to access its established clinical delivery infrastructure.
The world-first service will provide a structured pathway for drug sponsors and clinical research organisations (CROs) to deliver complex treatment protocols through Emyria’s Empax network, supporting clinical trial execution and post-approval commercial rollout.
It positions the company as a global clinical delivery platform and establishes a dual-revenue model combining existing reimbursed treatment programs with high-margin, sponsor-funded services.
Sponsor-funded clinical delivery is expected to command premium commercial rates, reflecting the complexity and scarcity of the required expertise and infrastructure.
Clinical Delivery Execution
Under the terms of the partnership program, international drug sponsors will engage Emyria to plan and execute clinical delivery by leveraging existing infrastructure, clinicians, and governance systems.
This system enables rapid deployment of complex clinical protocols, along with reduced execution risk for sponsors and efficient scaling from clinical trials through to commercial rollout.
Emyria said its high-margin, capital-light services model continued to receive positive inbound interest from sponsors and CROs seeking scalable and compliant clinical delivery solutions.
North American sponsor Psyence Group has already signed up, allowing Emyria to become a clinical trial site for a Phase IIb trial in adjustment disorder for patients with advanced cancer.
“Our ambition is to play a leading global role in enabling these therapies to reach patients at scale, while generating high-margin, capital-light revenue for the company,” executive chair Greg Hutchinson said.
Therapy Program Development
More than 50 psychedelic-assisted therapy programs are currently in clinical development across the globe, targeting large and under-served patient populations with post-traumatic stress disorder, treatment-resistant depression, and other serious mental health conditions.
Unlike traditional pharmaceuticals, these therapies require intensive psychotherapy, long-duration treatment sessions, purpose-built clinical environments, and involve highly trained and multi-disciplinary teams.
Industry research shows that clinical delivery capacity (rather than drug development) is emerging as a primary constraint to the global rollout of these new programs.
This dynamic is being reinforced by accelerating government and regulatory momentum.
This is especially so in the US, where recently policy initiatives have focused on accelerating research on psychedelic drugs with a view to expediting medical treatments for serious mental illness.
